



**COLORADO**

Department of Health Care  
Policy & Financing

**AGENDA**  
**Pharmaceuticals & Therapeutics Committee**  
**Department of Health Care Policy & Financing**

Zoom Webinar: TBD  
Tuesday, April 8, 2025, 1:00-5:00 P.M. MST

**1. Committee Member Introductions**

**2. Unfinished Business and General Orders**

Approval of minutes from January 07, 2025 P&T meeting  
Updates from January 07, 2025 P&T Meeting

**3. New Business**

Updates from the Prior Authorization Call Center

**4. Drug Classes Up for Review**

Review of Buprenorphine, Injectable  
Review of Tetracyclines  
Review of PAH Therapies  
    PDEIs, Endothelin Antagonists, Prostanoids & Guanylate Cyclase Stimulators  
Review of Statins & Combinations  
Movement Disorder Agents  
Review of Acne Agents, Topical  
Review of Immunomodulators, Topical  
    Atopic Dermatitis, Antineoplastics & Other Agents  
Review of H. Pylori Treatments  
Review of Proton Pump Inhibitors

Mass review drug classes:

- Alpha-Blockers
- Beta-Blockers - Single Agent, Anti-Arrhythmics & Combinations
- Calcium Channel Blockers - DHPs & Non-DHPs
- Angiotensin Converting Enzyme (ACE) Inhibitors & Combinations
- Angiotensin Receptor Blockers (ARBs) & Combinations
- Renin Inhibitors & Combinations
- Lipotropics - Bile Acid Sequestrants, Fibrates & Other Agents
- Acne Agents, Oral Isotretinoin
- Anti-Psoriatics - Oral & Topical
- Rosacea Agents



- Topical Steroids - Low, Medium, High & Very High Potency
- Bile Salts
- Anti-Emetics - Oral & Non-Oral
- GI Motility, Chronic
- Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents
- Pancreatic Enzymes
- Proton Pump Inhibitors
- Non-Biologic Ulcerative Colitis - Oral & Rectal
- Anticoagulants - Oral & Parenteral
- Anti-Platelets
- Colony Stimulating Factors
- Erythropoiesis Stimulating Agents

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Erik Hamel, Pharmacist Account Executive, [erik.hamel@primetherapeutics.com](mailto:erik.hamel@primetherapeutics.com) and carbon copy: Greg Miller, PDL & Clinical Strategy Pharmacist, [greg.l.miller@state.co.us](mailto:greg.l.miller@state.co.us). Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **April 1<sup>st</sup>, 2025 by 5pm MST.**

## 5. Adjourn

Upcoming Meeting Date: July 8, 2025.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](mailto:504/ADA) or [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

